EGFR and non-small cell lung carcinoma: used the CancerLinQ database to examine treatment patterns and survival of patients with EGFR-mutated advanced NSCLC diagnosed in 2011–2018 who received first-line therapy with a first- or second-generation EGFR TKI (29).